SYNTHORX, INC.
🏢 View company profile →10Patents
10Active
10Granted
52Portfolio score
Filing activity: Aug 3, 2018 → Oct 4, 2023
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10610571B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | Emerging Cross-Sectional Technologies | 20 | Active |
| US11077195B2 | IL-2 conjugates and methods of use thereof | Human Necessities | 6 | Active |
| US11622993B2 | Cytokine conjugates for the treatment of autoimmune diseases | Emerging Cross-Sectional Technologies | 5 | Active |
| US11701407B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | Emerging Cross-Sectional Technologies | 4 | Active |
| US11834689B2 | Incorporation of unnatural nucleotides and methods thereof | Chemistry; Metallurgy | 1 | Active |
| US12318431B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | Emerging Cross-Sectional Technologies | 0 | Active |
| US12319944B2 | Incorporation of unnatural nucleotides and methods thereof | Chemistry; Metallurgy | 0 | Active |
| US12377131B2 | Cytokine conjugates for the treatment of autoimmune diseases | Emerging Cross-Sectional Technologies | 0 | Active |
| US11919934B2 | IL-15 conjugates and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12234271B2 | Il-2 conjugates and methods of use to treat autoimmune diseases | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.